I will be brutally honest...that was no mere "sandwich", you gave us a "buffet" of points to contend with. You were not far fetched. So, let's focus on one point for clarity. Do you mean to market or merely approved? If they get it to market, as in selling it, that would mean they have sales/marketing channels all nailed down. If they do that then one of two things occurred - they have a partner or they created their own in-house functions. I do not believe they have the time to do the latter effectively. That means it will be a partnership that must be nailed down.
Here are my bifurcated thoughts put to you simply...
As a shareholder, the biggest payout would be if they partnered for sales/marketing/distribution and took care of the rest themselves. That would put shareholders in the position to make up their minds at what price to sell; as the company would continue on its own. There is the thought that, with such a large chunck of stock Nasrat is an impediment because, should he sell, whether as part of a schedule or not, the p/s will take a hit. That is reality.
As a shareholder, the quickest payout (though likely lower) would be if they were bought out. However, my belief in their buyout is not based on Elite. Anyone who has read my posts talking strategy should know that it is the competitive environment that is driving M&A in pharma at the highest level since 2009 and if Elite files an NDA and we know their tech is plug and play, I am telling you that it is a fact that a big pharma firm will have run the numbers and make an offer that Elite cannot refuse. So, it is my belief in the competitive environment more than Elite that expects Elite to be bought. At what price? Too many moving parts for me to predict the top end. But, the bottom end? Easily north of $3.5 Billion. Why do I say that? Do an inflation adjusted price on the acquisition of King by Pfizer and compare the Elite pipeline - ADF and generics - to what King had and you can easily see how Elite could fetch such a price. Nasrat knows this, as do many.
